Essential medicines and access to insulin

Geoff Gill; John S Yudkin; Solomon Tesfaye; Maximilian de Courten; Edwin Gale; Ayesha Motala; Kaushik Ramaiya; Nigel Unwin; Sarah Wild

doi:10.1016/s2213-8587(17)30090-6

Essential medicines and access to insulin

Geoff Gill, John S Yudkin, Solomon Tesfaye, Maximilian de Courten, Edwin Gale, Ayesha Motala, Kaushik Ramaiya, Nigel Unwin, Sarah Wild

Clinical Sciences

Liverpool School of Tropical Medicine

Research output: Contribution to journal › Letter › peer-review

4 Citations (Scopus)

Abstract

We fully support the views expressed in The Lancet Diabetes & Endocrinology's Editorial about ensuring affordable access to insulin and the proposal to add analogue insulin to the WHO Essential Medicines list. The International Insulin Foundation in its 2011 position statement called for “the universal access for persons with type 1 diabetes to life-saving and life-preserving insulin”. In 2012, we launched the 100 Campaign, which sets the target of 100% affordability and 100% availability of insulin worldwide by the year 2022 (100 years after the introduction of insulin for people with diabetes).

Original language	English
Pages (from-to)	324-325
Number of pages	2
Journal	Lancet Diabetes and Endocrinology
Volume	5
Issue number	5
Early online date	15 Mar 2017
DOIs	https://doi.org/10.1016/s2213-8587(17)30090-6
Publication status	Published - 1 May 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/s2213-8587(17)30090-6

Lancet Essential medicines 15 3 17Final published version, 36.4 KB

Cite this

@article{d9b39ac5560347068f6e9ef7c112ec53,

title = "Essential medicines and access to insulin",

abstract = "We fully support the views expressed in The Lancet Diabetes \& Endocrinology's Editorial about ensuring affordable access to insulin and the proposal to add analogue insulin to the WHO Essential Medicines list. The International Insulin Foundation in its 2011 position statement called for “the universal access for persons with type 1 diabetes to life-saving and life-preserving insulin”. In 2012, we launched the 100 Campaign, which sets the target of 100\% affordability and 100\% availability of insulin worldwide by the year 2022 (100 years after the introduction of insulin for people with diabetes).",

author = "Geoff Gill and Yudkin, \{John S\} and Solomon Tesfaye and \{de Courten\}, Maximilian and Edwin Gale and Ayesha Motala and Kaushik Ramaiya and Nigel Unwin and Sarah Wild",

year = "2017",

month = may,

day = "1",

doi = "10.1016/s2213-8587(17)30090-6",

language = "English",

volume = "5",

pages = "324--325",

journal = "Lancet Diabetes and Endocrinology",

issn = "2213-8587",

publisher = "Elsevier",

number = "5",

}

TY - JOUR

T1 - Essential medicines and access to insulin

AU - Gill, Geoff

AU - Yudkin, John S

AU - Tesfaye, Solomon

AU - de Courten, Maximilian

AU - Gale, Edwin

AU - Motala, Ayesha

AU - Ramaiya, Kaushik

AU - Unwin, Nigel

AU - Wild, Sarah

PY - 2017/5/1

Y1 - 2017/5/1

N2 - We fully support the views expressed in The Lancet Diabetes & Endocrinology's Editorial about ensuring affordable access to insulin and the proposal to add analogue insulin to the WHO Essential Medicines list. The International Insulin Foundation in its 2011 position statement called for “the universal access for persons with type 1 diabetes to life-saving and life-preserving insulin”. In 2012, we launched the 100 Campaign, which sets the target of 100% affordability and 100% availability of insulin worldwide by the year 2022 (100 years after the introduction of insulin for people with diabetes).

AB - We fully support the views expressed in The Lancet Diabetes & Endocrinology's Editorial about ensuring affordable access to insulin and the proposal to add analogue insulin to the WHO Essential Medicines list. The International Insulin Foundation in its 2011 position statement called for “the universal access for persons with type 1 diabetes to life-saving and life-preserving insulin”. In 2012, we launched the 100 Campaign, which sets the target of 100% affordability and 100% availability of insulin worldwide by the year 2022 (100 years after the introduction of insulin for people with diabetes).

U2 - 10.1016/s2213-8587(17)30090-6

DO - 10.1016/s2213-8587(17)30090-6

M3 - Letter

SN - 2213-8587

VL - 5

SP - 324

EP - 325

JO - Lancet Diabetes and Endocrinology

JF - Lancet Diabetes and Endocrinology

IS - 5

ER -

Essential medicines and access to insulin

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this